A bad dream come true: ICT patent prosecution against EU competition law

The article scrutinises patent prosecution practices in the ICT sector under Arts. 101 and 102 TFEU in light of the CJEU case law and economic arguments pointing to their anti- and pro-competitive effects. Although the data on European ICT patent prosecution reveals a ‘bad dream’ of entry barrier f...

Full description

Saved in:
Bibliographic Details
Main Author: Niccolò Galli
Format: Article
Language:English
Published: Universidade Católica Editora 2022-11-01
Series:Market and Competition Law Review
Subjects:
Online Access:https://revistas.ucp.pt/index.php/mclawreview/article/view/11716
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850086760500953088
author Niccolò Galli
author_facet Niccolò Galli
author_sort Niccolò Galli
collection DOAJ
description The article scrutinises patent prosecution practices in the ICT sector under Arts. 101 and 102 TFEU in light of the CJEU case law and economic arguments pointing to their anti- and pro-competitive effects. Although the data on European ICT patent prosecution reveals a ‘bad dream’ of entry barrier features prone to anti-competitive practices, the article acknowledges the limited scope under the existing jurisprudence for EU competition law intervention to awaken from it. Indeed, the data on the European ICT patent landscape hint at substantial patent prosecution cost and timing, rising patent applications and granted patents owned by a few large ICT undertakings, and rare administrative oppositions, especially between symmetric firms. Despite the competition policy appeal of collusive cross-licensing agreements coordinating the parties’ ICT patent prosecution strategies to the detriment of technology competition, their investigation under Art. 101 TFEU is yet to be seen. However, the offered evidence suggesting restrictions of competition in ICT technology markets coupled with the anti-competitive findings of the recent Consumer IoT Sector inquiry might justify a follow-on inquiry limited to ICT cross-licensing agreements. Regarding Art. 102 TFEU, the article concludes that the AstraZeneca jurisprudence on abusive patent prosecution is of a limited application for anti-competitive ICT patenting practices that essentially concern blocking patents. Absent fundamental patent law reforms, EU competition law remains not only a second-best solution to address the depicted bad dream of the ICT patent landscape, but also a very remote one.
format Article
id doaj-art-76b4ba9f7dd8437dbf5521972da45671
institution DOAJ
issn 2184-0008
language English
publishDate 2022-11-01
publisher Universidade Católica Editora
record_format Article
series Market and Competition Law Review
spelling doaj-art-76b4ba9f7dd8437dbf5521972da456712025-08-20T02:43:23ZengUniversidade Católica EditoraMarket and Competition Law Review2184-00082022-11-016210.34632/mclawreview.2022.11716A bad dream come true: ICT patent prosecution against EU competition lawNiccolò Galli0European University Institute The article scrutinises patent prosecution practices in the ICT sector under Arts. 101 and 102 TFEU in light of the CJEU case law and economic arguments pointing to their anti- and pro-competitive effects. Although the data on European ICT patent prosecution reveals a ‘bad dream’ of entry barrier features prone to anti-competitive practices, the article acknowledges the limited scope under the existing jurisprudence for EU competition law intervention to awaken from it. Indeed, the data on the European ICT patent landscape hint at substantial patent prosecution cost and timing, rising patent applications and granted patents owned by a few large ICT undertakings, and rare administrative oppositions, especially between symmetric firms. Despite the competition policy appeal of collusive cross-licensing agreements coordinating the parties’ ICT patent prosecution strategies to the detriment of technology competition, their investigation under Art. 101 TFEU is yet to be seen. However, the offered evidence suggesting restrictions of competition in ICT technology markets coupled with the anti-competitive findings of the recent Consumer IoT Sector inquiry might justify a follow-on inquiry limited to ICT cross-licensing agreements. Regarding Art. 102 TFEU, the article concludes that the AstraZeneca jurisprudence on abusive patent prosecution is of a limited application for anti-competitive ICT patenting practices that essentially concern blocking patents. Absent fundamental patent law reforms, EU competition law remains not only a second-best solution to address the depicted bad dream of the ICT patent landscape, but also a very remote one. https://revistas.ucp.pt/index.php/mclawreview/article/view/11716AntitrustIntellectual propertyInnovationPatentsPatent applications
spellingShingle Niccolò Galli
A bad dream come true: ICT patent prosecution against EU competition law
Market and Competition Law Review
Antitrust
Intellectual property
Innovation
Patents
Patent applications
title A bad dream come true: ICT patent prosecution against EU competition law
title_full A bad dream come true: ICT patent prosecution against EU competition law
title_fullStr A bad dream come true: ICT patent prosecution against EU competition law
title_full_unstemmed A bad dream come true: ICT patent prosecution against EU competition law
title_short A bad dream come true: ICT patent prosecution against EU competition law
title_sort bad dream come true ict patent prosecution against eu competition law
topic Antitrust
Intellectual property
Innovation
Patents
Patent applications
url https://revistas.ucp.pt/index.php/mclawreview/article/view/11716
work_keys_str_mv AT niccologalli abaddreamcometrueictpatentprosecutionagainsteucompetitionlaw
AT niccologalli baddreamcometrueictpatentprosecutionagainsteucompetitionlaw